Bayer fourth in IVD (in vitro diagnostics) market after $1.1 billion acquisition
This article was originally published in Clinica
Bayer Diagnostics is to buy Chiron's diagnostic division, for $1.1 billion. The acquisition moves Bayer to fourth place overall in the IVD market worldwide, behind Roche Boehringer Mannheim, Abbott Laboratories and Johnson & Johnson.
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.